ALSENLITE: Senolytics for Alzheimer's Disease

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Mild Cognitive ImpairmentAlzheimer Disease
Interventions
DRUG

Dasatinib

100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles

DRUG

Quercetin

Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04785300 - ALSENLITE: Senolytics for Alzheimer's Disease | Biotech Hunter | Biotech Hunter